Narayana Hrudayalaya Limited is a multinational healthcare service provider with a significant and diversified operational footprint across India, the Cayman Islands, and the United Kingdom. As of early 2026, the company manages a network of 55 healthcare facilities, comprising hospitals, surgical centers, heart centers, and clinics, with a total of 5,933 operational beds out of a total capacity of 6,245. The organization is supported by a large workforce of approximately 20,500 individuals, of which around 12,500 are clinical staff. In its home market of India, Narayana Health operates 18 owned or operated hospitals and multiple ancillary facilities, strategically clustered in the South, East, North, and West regions, with the East and South representing the largest concentration of operational beds. The company has established a strong reputation in high-complexity tertiary care, with Cardiac Sciences being its most significant specialty, contributing 33% of its Indian hospital revenue. This is complemented by other key areas such as Medicine & GI Sciences, Oncology, and Renal Sciences. The business model includes a mix of owned hospitals, operated hospitals on a rental/revenue-sharing basis, and a growing integrated care segment. The company's international presence includes two facilities in the Cayman Islands and a newly acquired, substantial network of 13 facilities in the United Kingdom, marking a major strategic expansion into a new geography.

Official Website: http://www.narayanahealth.org/

• Consolidated Performance (Q3 FY26): The company reported consolidated operating revenues of ₹21,512 Mn, marking a substantial growth of 61.2% year-over-year (YoY). This growth was primarily driven by the consolidation of the newly acquired UK operations. Consolidated EBITDA stood at ₹3,904 Mn with a margin of 18.2%, and Profit After Tax (PAT) was ₹1,281 Mn, yielding a PAT margin of 6.0%.

• Adjusted Profitability (Q3 FY26): Reported earnings were impacted by one-time costs. After adjusting for a ₹757 Mn acquisition cost and a ₹509 Mn exceptional item related to a new labor code, the adjusted EBITDA was ₹4,662 Mn (21.7% margin) and adjusted PAT was ₹2,548 Mn (11.8% margin). These adjusted figures provide a clearer view of the underlying operational profitability.

• India Operations Performance (Q3 FY26): The standalone India business generated total revenue of ₹11,780 Mn, reflecting a healthy organic growth of 11.7% YoY. The India operations remain the stable core of the business, demonstrating consistent growth.

• International Operations Performance (Q3 FY26): The Cayman Islands operations reported hospital revenues of US$ 44.8 Mn, a 27.1% YoY increase. The newly acquired UK operations contributed ₹4,902 Mn in revenue from the effective date of acquisition (November 6, 2025).

• Balance Sheet Strength: As of December 31, 2025, the company's net debt (Total Borrowings less Cash & Investments) stood at ₹22,321 Mn. The net debt-to-equity ratio is at a manageable level of 0.53. A notable portion of the company's debt, US $119 Mn and GBP £150 Mn, is denominated in foreign currency.

Summary: The company delivered strong top-line growth driven by the strategic UK acquisition, though reported profits were suppressed by significant one-time expenses; underlying operational performance and organic growth in India remain robust.

• Diversified International Footprint: Unlike many of its domestic peers, Narayana Health has a significant and expanding international presence. The established high-revenue operations in the Cayman Islands are now complemented by a large-scale entry into the UK market, diversifying its revenue streams and geographical risk.

• Deep Specialization in Complex Care: The company derives a significant portion of its revenue (33%) from Cardiac Sciences, a high-margin, high-complexity specialty. This deep clinical expertise, demonstrated by milestones like performing 244 robotic cardiac surgeries in a single quarter, creates a strong competitive moat.

• Focus on Digital Transformation: Narayana Health is actively leveraging technology to enhance efficiency and patient experience. Initiatives like the "ATHMA" platform for care providers, a patient app with over 3.7 million installs, and the "AADI" clinical messaging system highlight a commitment to integrating digital solutions into its core operations.

• Integrated Healthcare Ecosystem: The company operates beyond the traditional hospital model by running an integrated care business, including clinics and an insurance arm. This allows it to capture a larger share of the patient's healthcare spending and build a more comprehensive ecosystem.

Summary: Narayana Health's unique position is built on its diversified international presence, deep expertise in complex medical specialties, and a forward-looking strategy centered on digital innovation.

• Inorganic Growth via UK Acquisition: The primary driver of the 61.2% YoY consolidated revenue growth in Q3 FY26 was the acquisition in the United Kingdom. This strategic move has immediately scaled the company's size and provided access to a mature healthcare market.

• Strong Organic Growth in International Markets: The Cayman Islands operations continue to be a strong growth engine, with hospital revenues increasing by 27.1% YoY in USD terms. This demonstrates the company's ability to successfully operate and grow in international markets.

• Stable Growth in Core India Market: The Indian operations delivered a steady revenue growth of 11.7% YoY. This was supported by a 5% YoY increase in hospital discharges in the key Bangalore cluster and a 9% increase in the Eastern Peripheral cluster.

• Increasing Revenue Per Patient: In India, the Average Revenue Per Occupied Bed (ARPOB) increased from ₹15.8 Mn in Q3 FY25 to ₹18.1 Mn in Q3 FY26, indicating a better specialty mix, price revisions, or higher patient acuity.

Summary: Growth is being propelled by a powerful dual-engine strategy: aggressive inorganic expansion into new geographies and consistent, healthy organic growth in its established core markets.

• Current Capacity: The company currently has a total bed capacity of 6,245, with 5,933 beds operational across its global network.

• Significant Capex Pipeline: Narayana Health has a robust expansion plan with a budgeted capex of over ₹7,600 Mn for FY26. A majority of this (₹4,240 Mn) is allocated for greenfield projects and inorganic growth, signaling a strong focus on future expansion.

• Key Greenfield and Expansion Projects:

• HSR, Bangalore: A 215-bed greenfield project with a cost of ₹4,900 Mn, expected to be completed in FY28.

• Rajarhat, Kolkata: A 350-bed greenfield hospital with a project cost of ₹9,000 Mn, also targeting an FY28 completion.

• Raipur Expansion: A 300-bed expansion project costing ₹5,400 Mn, with an FY28 timeline.

• Bangalore Expansion: Multiple other projects in Bangalore (Central, South, South-West) are in various stages of design and construction, adding another 670 beds.

Summary: The company is in a major investment cycle, executing a well-defined capex strategy to add nearly 2,000 beds by FY30, primarily focused on strengthening its presence in its flagship regions of Bangalore and Kolkata.

• Targeted Bed Capacity Expansion: The company has a clear target to increase its bed capacity from the current 5,750 to 7,685 by FY30. This structured expansion provides a visible roadmap for future organic growth.

• Long-Term ESG Commitments: Narayana Health has laid out an ambitious ESG vision called "Health For All." Key long-term goals include:

• Achieving Carbon Neutrality by 2040.

• Utilizing a 50% renewable energy mix by 2030.

• Training over 25,000 doctors, nurses, and paramedical staff by 2030.

• Digitizing patient safety and experience, aiming for a "Zero Trust Architecture" for cyber resilience by 2026.

Summary: The company's future strategy is anchored on significant, planned capacity expansion to drive organic growth and a comprehensive, long-term commitment to sustainability and social responsibility.

• Consolidated Margin Profile: In Q3 FY26, the reported consolidated EBITDA margin was 18.2%, and the PAT margin was 6.0%. These were compressed due to acquisition-related costs.

• Adjusted Margin Strength: When excluding one-time costs, the adjusted consolidated EBITDA margin was a healthy 21.7%, demonstrating the strong underlying profitability of the combined entity.

• Robust India Hospital Margins: The core India hospital business continues to be highly profitable, recording an EBITDA margin of 22.7% in Q3 FY26, down slightly from 23.8% in the previous quarter but up significantly from 19.7% in the prior year.

• Cost Structure Analysis: The cost structure for the India business is stable, with the largest components being Consumable Expenses (28% of operating revenues), and Doctors and Nurses costs (23%). This indicates disciplined cost management in the core business.

Summary: While one-time acquisition expenses have impacted reported consolidated margins, the underlying profitability remains strong, anchored by the high-margin core India hospital business.

• Acquisition and Integration Risk: The large-scale acquisition in the UK brings significant integration challenges. The financial impact is already visible through one-time acquisition costs (₹757 Mn) and future amortization of intangible assets, which could weigh on reported profitability.

• Foreign Currency Exposure: The company holds a significant amount of debt denominated in foreign currencies (US $119 Mn and GBP £150 Mn). This exposes its earnings to volatility in INR, USD, and GBP exchange rates, which can impact finance costs and profitability.

• Regulatory and Policy Risk: The company recorded an exceptional charge of ₹509 Mn due to a "new labor code." This highlights its vulnerability to changes in government regulations and labor laws, which can lead to unforeseen costs.

• Project Execution Risk: The company is undertaking multiple large-scale greenfield and expansion projects simultaneously. Any delays in execution or cost overruns on these capital-intensive projects could impact future financial performance and return on capital.

Summary: The primary risks facing the company are centered on the successful integration of its UK acquisition, managing foreign currency volatility on its debt, and executing its ambitious expansion plans on time and within budget.

• Clinical Excellence and Milestones: The company continues to demonstrate leadership in clinical innovation. Key achievements in Q3 FY26 include the first-ever heart transplant at its Ahmedabad hospital and significant advancements in robotic cardiac surgeries and complex pediatric interventions at its flagship Bangalore and Howrah units.

• Shareholding Pattern: As of December 31, 2025, the Promoter Group maintains a controlling stake of 63.3%, ensuring strategic continuity. The company also has a strong base of institutional investors, with Foreign Institutional Investors (FIIs) holding 11.1% and Domestic Institutional Investors (DIIs) holding 9.4%, which signals confidence from the professional investment community.

Summary: The company continues to reinforce its reputation for clinical excellence through notable medical achievements, all while being supported by a stable and confident ownership structure.